FDA Approves FluMist's Use in Young Children

Published on: 

The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2?5.

The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2–5. Approval for the vaccine was previously limited to healthy children 5 years of age and older and adults up to age 49.

Before this approval, there were only two vaccines licensed in the US for children under the age of 5. One of the vaccines, Fluzone, is indicated for people over 6 months of age, while Fluvirin, the other vaccine, is for use in children age 4 and older.

Advertisement

FDA release